VAXCYTE INC (PCVX) Stock Income Statement
USA - NASDAQ:PCVX - US92243G1085 - Common Stock
48.69 USD
+3.14 (+6.89%)
49.5 USD
+0.81 (+1.66%)
| TTM (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 811.56M | 569.55M | 393.04M | 209.26M | 103.67M | |||
| Research and Development | 685.86M | 476.64M | 332.34M | 135.68M | 60.94M | |||
| Selling, General, and Administrative Expenses | 125.70M | 92.90M | 60.70M | 73.59M | 42.74M | |||
| Operating Income | -811.56M | -569.55M | -393.04M | -209.26M | -103.67M | |||
| Interest Income/Expense | 129.72M | 109.99M | 61.01M | 6.88M | 2.01M | |||
| Other Income/Expense | 24.64M | -4.38M | 4.76M | 1.93M | 1.59M | |||
| Non Recurring Items | null | 0 | -75.00M | -23.04M | null | |||
| Income Before Taxes | -657.20M | -463.93M | -402.27M | -223.49M | -100.08M | |||
| Income Tax | null | null | null | null | null | |||
| Net Income | -657.20M | -463.93M | -402.27M | -223.49M | -100.08M | |||
| EBITDA | -806.72M | -562.54M | -389.88M | -206.68M | -101.87M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -4.8382000000000005 | -3.8028 | -4.1403 | -3.44 | -1.93 | |||
| Non GAAP EPS | -4.8340000000000005 | -3.794 | -4.13 | -3.43 | -1.93 | |||
| Statistics | ||||||||
All data in USD